title: Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis.
abstract: The effects of diabetes and lipoprotein lipase (LpL) on plasma lipids were studied in mice expressing human apolipoprotein B (HuBTg). Our overall objective was to produce a diabetic mouse model in which the sole effects of blood glucose elevation on atherosclerosis could be assessed. Mice were made diabetic by intraperitoneal injection of streptozotocin, which led to a 2- to 2. 5-fold increase in plasma glucose. Lipids were assessed in mice on chow and on an atherogenic Western type diet (WTD), consisting of 21% (wt/wt) fat and 0.15% (wt/wt) cholesterol. Plasma triglyceride and cholesterol were the same in diabetic and non-diabetic mice on the chow diet. On the WTD, male diabetic HuBTg mice had a >50% increase in plasma cholesterol and more very low density lipoprotein (VLDL) cholesterol and triglyceride as assessed by FPLC analysis. A Triton study showed no increase in triglyceride or apolipoprotein B production, suggesting that the accumulation of VLDL was due to a decrease in lipoprotein clearance. Surprisingly, the VLDL increase in these mice was not due to a decrease in LpL activity in postheparin plasma. To test whether LpL overexpression would alter these diabetes-induced lipoprotein changes, HuBTg mice were crossed with mice expressing human LpL in muscle. LpL overexpression reduced plasma triglyceride, but not cholesterol, in male mice on WTD. Aortic root atherosclerosis assessed in 32-week-old mice on the WTD was not greater in diabetic mice. In summary, diabetes primarily increased plasma VLDL in HuBTg mice. LpL activity was not decreased in these animals. However, additional LpL expression eliminated the diabetic lipoprotein changes. These mice did not have more atherosclerosis with diabetes.
authors.affiliation: Department of Medicine, Division of Nutrition and Preventive Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Kako
authors.forename: L S
authors.initials: LS
authors.lastname: Huang
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: T
authors.initials: T
authors.lastname: Katopodis
authors.forename: R
authors.initials: R
authors.lastname: Ramakrishnan
authors.forename: I J
authors.initials: IJ
authors.lastname: Goldberg
mesh_terms: D000821:Animal Feed; D000818:Animals; D001055:Apolipoproteins B / Q000096:biosynthesis / Q000235:genetics; D001161:Arteriosclerosis / Q000209:etiology; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002850:Chromatography, Gel; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D005260:Female; D006801:Humans; D008071:Lipoprotein Lipase / Q000097:blood; D008074:Lipoproteins / Q000737:chemistry / Q000187:drug effects / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic / Q000378:metabolism*; D012737:Sex Factors; D014280:Triglycerides / Q000096:biosynthesis
chemical_list: D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D008071:Lipoprotein Lipase